Hard to value?
1,620m (Market Cap) - 210m (Cash as of 30th September) - 50m (Cash from Milestone Payment = 1.36b~ EV.
We are going to earn between 216-218m in net income. Our expenses in H1 include R&D was 20m, so our full year expenses are likely to be 40m~. That is 176m pre-tax profit.
That is a forward PE of 7.40~ on 2024 numbers and 6.4~ trailing on pre-tax earnings.
Note: pre-tax (2023 was 205m pre tax profit, 157m NPAT)
Yes there are impacts of one off in that equation but there are still plenty one-off payments due to be paid over the next few calendar years, particulary when ACAD expands Daybue into RoW.
And what is the value for NNZ-2591 in this equation? right now it's a a negative value - even with the most conservative of estimates. We also have no debt, and our product is the only approved product but there's zero credit given in our valuation.
- Forums
- ASX - By Stock
- NEU
- Share Price
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.31%
!
$17.78

Share Price, page-13289
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$17.78 |
Change
0.230(1.31%) |
Mkt cap ! $2.240B |
Open | High | Low | Value | Volume |
$17.83 | $17.99 | $17.35 | $16.12M | 911.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 11000 | $17.40 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.80 | 10070 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11000 | 17.400 |
2 | 2732 | 17.300 |
1 | 300 | 17.100 |
1 | 58 | 17.060 |
1 | 10 | 17.040 |
Price($) | Vol. | No. |
---|---|---|
17.800 | 70 | 1 |
17.940 | 566 | 1 |
17.990 | 73 | 1 |
18.000 | 4313 | 4 |
18.100 | 611 | 2 |
Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
NEU (ASX) Chart |